Residual Effects of Fresh and Composted Dairy Manure Applications on Potato Production

Potato growers in Idaho and other dairy producing regions often grow potatoes on fields that have had a history of fresh and composted manure applications. Growers remain uncertain of the impacts that previous manure applications will have on tuber yield and quality, as well as diseases, physiological disorders, and contamination by human pathogenic bacteria such as E. coli. The focus of this study was to determine the long term effects of manure, compost, and chemical phosphorus (P) fertilizer applications on tuber yields, tuber quality, nutrient uptake, tuber disorders and diseases, and soil nutrient concentrations. Russet Burbank potatoes were grown in 2008 and 2009 on plots that had received dairy manure, dairy compost, P fertilizer, or no P source (control) at the same target P rate in 2003, 2004, and 2005. Compared with the P fertilizer treatment, applications of manure and/or compost significantly increased total yields, soil potassium (K), soil nitrate (NO3-N), early season petiole P, and late season petiole K in at least one year of the two-year study. There were no significant differences between P fertilizer, manure, and compost treatments on soil test P, late season petiole P, early season petiole K, E. coli populations on tuber surfaces, common tuber diseases and disorders, and tuber quality. Based on our findings, tuber yields significantly increased three years after applications of fresh and composted dairy manure, while tuber diseases, disorders, and quality were not affected

Asymptotic completeness in a class of massless relativistic quantum field theories

This paper presents the first examples of massless relativistic quantum field theories which are interacting and asymptotically complete. These two-dimensional theories are obtained by an application of a deformation procedure, introduced recently by Grosse and Lechner, to chiral conformal quantum field theories. The resulting models may not be strictly local, but they contain observables localized in spacelike wedges. It is shown that the scattering theory for waves in two dimensions, due to Buchholz, is still valid under these weaker assumptions. The concepts of interaction and asymptotic completeness, provided by this theory, are adopted in the present investigation.Comment: 15 pages, LaTeX. As appeared in Communications in Mathematical Physic

A 2D Luttinger model

A detailed derivation of a two dimensional (2D) low energy effective model for spinless fermions on a square lattice with local interactions is given. This derivation utilizes a particular continuum limit that is justified by physical arguments. It is shown that the effective model thus obtained can be treated by exact bosonization methods. It is also discussed how this effective model can be used to obtain physical information about the corresponding lattice fermion system.Comment: 36 pages, 3 figures; v2: 36 pages, 2 figures, minor corrections; v3: 38 pages, 2 figures, clarifications and minor corrections, adapted to follow-up paper arXiv:0907.127

Measurement of e+e- -> pi+pi- cross section with CMD-2 around rho-meson

The cross section of the process e+e- -> pi+pi- has been measured using about 114000 events collected by the CMD-2 detector at the VEPP-2M e+e- collider in the center-of-mass energy range from 0.61 to 0.96 GeV. Results of the pion form factor determination with a 0.6% systematic uncertainty are presented. Implications for the hadronic contribution to the muon anomalous magnetic moment are discussed.Comment: 17 pages, 4 figures, submitted to PL

Randomized trial of standard adjuvant chemotherapy regimens versus capecitabine in older women with early breast cancer: 10-year update of the CALGB 49907 trial

PURPOSE Older women with breast cancer remain under-represented in clinical trials. The Cancer and Leukemia Group B 49907 trial focused on women age 65 years and older. We previously reported the primary analysis after a median follow-up of 2.4 years. Standard adjuvant chemotherapy showed significant improvements in recurrence-free survival (RFS) and overall survival compared with capecitabine. We now update results at a median follow-up of 11.4 years. PATIENTS AND METHODS Patients age 65 years or older with early breast cancer were randomly assigned to either standard adjuvant chemotherapy (physician's choice of either cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide and doxorubicin) or capecitabine. An adaptive Bayesian design was used to determine sample size and test noninferiority of capecitabine. The primary end point was RFS. RESULTS The design stopped accrual with 633 patients at its first sample size assessment. RFS remains significantly longer for patients treated with standard chemotherapy. At 10 years, in patients treated with standard chemotherapy versus capecitabine, the RFS rates were 56% and 50%, respectively (hazard ratio [HR], 0.80; P = .03); breast cancer-specific survival rates were 88% and 82%, respectively (HR, 0.62; P = .03); and overall survival rates were 62% and 56%, respectively (HR, 0.84; P = .16). With longer follow-up, standard chemotherapy remains superior to capecitabine among hormone receptor-negative patients (HR, 0.66; P = .02), but not among hormone receptor-positive patients (HR, 0.89; P = .43). Overall, 43.9% of patients have died (13.1% from breast cancer, 16.4% from causes other than breast cancer, and 14.1% from unknown causes). Second nonbreast cancers occurred in 14.1% of patients. CONCLUSION With longer follow-up, RFS remains superior for standard adjuvant chemotherapy versus capecitabine, especially in patients with hormone receptor-negative disease. Competing risks in this older population dilute overall survival benefits

Sacituzumab govitecan in metastatic triple-negative breast cancer

BACKGROUND: Patients with metastatic triple-negative breast cancer have a poor prognosis. Sacituzumab govitecan is an antibody-drug conjugate composed of an antibody targeting the human trophoblast cell-surface antigen 2 (Trop-2), which is expressed in the majority of breast cancers, coupled to SN-38 (topoisomerase I inhibitor) through a proprietary hydrolyzable linker. METHODS In this randomized, phase 3 trial, we evaluated sacituzumab govitecan as compared with single-agent chemotherapy of the physician's choice (eribulin, vinorelbine, capecitabine, or gemcitabine) in patients with relapsed or refractory metastatic triple-negative breast cancer. The primary end point was progression-free survival (as determined by blinded independent central review) among patients without brain metastases. RESULTS A total of 468 patients without brain metastases were randomly assigned to receive sacituzumab govitecan (235 patients) or chemotherapy (233 patients). The median age was 54 years; all the patients had previous use of taxanes. The median progression-free survival was 5.6 months (95% confidence interval [CI], 4.3 to 6.3; 166 events) with sacituzumab govitecan and 1.7 months (95% CI, 1.5 to 2.6; 150 events) with chemotherapy (hazard ratio for disease progression or death, 0.41; 95% CI, 0.32 to 0.52; P<0.001). The median overall survival was 12.1 months (95% CI, 10.7 to 14.0) with sacituzumab govitecan and 6.7 months (95% CI, 5.8 to 7.7) with chemotherapy (hazard ratio for death, 0.48; 95% CI, 0.38 to 0.59; P<0.001). The percentage of patients with an objective response was 35% with sacituzumab govitecan and 5% with chemotherapy. The incidences of key treatment-related adverse events of grade 3 or higher were neutropenia (51% with sacituzumab govitecan and 33% with chemotherapy), leukopenia (10% and 5%), diarrhea (10% and <1%), anemia (8% and 5%), and febrile neutropenia (6% and 2%). There were three deaths owing to adverse events in each group; no deaths were considered to be related to sacituzumab govitecan treatment. CONCLUSIONS Progression-free and overall survival were significantly longer with sacituzumab govitecan than with single-agent chemotherapy among patients with metastatic triple-negative breast cancer. Myelosuppression and diarrhea were more frequent with sacituzumab govitecan